Is ImmunoGen Stock a Bargain After Dropping 39%?
With ImmunoGen (NASDAQ: IMGN) shares sliding by more than 39% in the past 12 months, its investors are bound to be looking for salvation. What's more, despite recent clinical trial results that management hailed as positive, the biotech's stock just might continue to struggle in the run-up to potential regulatory approval for its first therapy.
But does the combination of a recent pullback and positive, late-stage clinical data make ImmunoGen an attractive purchase for value-conscious investors? Not really, and here's why.
Image source: Getty Images.
Source Fool.com
